Glonghui, March 4, 丨 Sipai Health (00314.HK) announced that for the year ended December 31, 2023 (“FY2023”), the Group expects that due to (i) organic growth in the Group's overall business; (ii) fair value losses on corporate convertible redeemable preferred shares (preferred shares issued to pre-initial public offering investors) as financial liabilities recorded in fiscal year 2023 after listing in December 2022; (iii) no profit or loss was recorded in fiscal year 2023 after listing; (iii) no listing was recorded in fiscal 2023 after listing Expenses; and (iv) the reduction in remuneration paid on a share-based basis in fiscal year 2023. Compared with adjusted loss of approximately RMB258.68 million (non-IFRS measurement) and annual loss of approximately RMB1,3717.6 million in 2022, adjusted loss during the year (non-IFRS measurement) and loss during the year are likely to narrow by more than 40% and 80%, respectively.
思派健康(00314.HK)：预计年内经调整亏损及年内亏损均可能收窄分别超过40%及80%
Spike Health (00314.HK): It is estimated that adjusted losses during the year and losses during the year may narrow by more than 40% and 80% respectively
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.